Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK105 Combined With Anlotinib in Persistent, Recurrent, and Metastatic Cervical Cancer
NCT05137171Phase 2Active, not recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- May 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of penpulimab and anlotinib in Cervical Cancer (CC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Objective Response Rate up to 24 months. Started May 2022; status: active, not recruiting.
02
Drugs
penpulimabanlotinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05137171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05137171.